1992 Nov;120(5):720-5
Cheng, J., Venkatesh, S., Ke, K., Barratt, M
2021;11:524 Pedrazzi JFC, Sales AJ, Ponciano RSM, Ferreira LG, Ferreira FR, Campos AC, et al
The key is understanding what is expected, what is temporary, and what deserves medical attention
These AEs are listed below with their rate of incidence in test subjects: Injection site reactions, like pruritus, rash, pain, and swelling (3.1%) Arthralgia (2.4%) Pain in the extremities (1.1%) Myalgia (1.1%) Peripheral edema (1.1%) Paresthesia (0.9%) Hypoesthesia (0.7%) Rash (0.7%) Dyspepsia (0.3%) Muscle pain (0.3%) Pruritus (0.3%) Vomiting (0.3%) Muscle stiffness (0.3%) Carpal Tunnel Syndrome (0.2%) Joint swelling (0.2%) Night sweats (0.2%) Palpitations (0.2%) Furthermore, clinical studies have linked tesamorelin to the following serious adverse events: Increased risk of glucose intolerance Increased risk of type 2 diabetes Disruption of hypothalamic-pituitary axis Neuropathies Lipoatrophy Diarrhea Fever Congestive heart failure Peripheral neuropathy Loss of mobility To date, no long-term tesamorelin studies involving healthy (non-elderly, non-HIV-infected) test subjects have been completed, suggesting that further research is merited
-1456x816.jpg.webp)
